Novo Nordisk A/S (NYSE:NVO) Shares Sold by Greenleaf Trust

Greenleaf Trust trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 35,804 shares of the company’s stock after selling 403 shares during the period. Greenleaf Trust’s holdings in Novo Nordisk A/S were worth $4,263,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in NVO. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at $25,000. Dixon Mitchell Investment Counsel Inc. acquired a new stake in Novo Nordisk A/S in the 1st quarter valued at $26,000. Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter valued at about $26,000. Finally, Gilliland Jeter Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 200.0% during the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.4 %

Shares of NYSE NVO traded down $0.51 during mid-day trading on Wednesday, reaching $115.96. The company had a trading volume of 95,823 shares, compared to its average volume of 4,270,290. Novo Nordisk A/S has a twelve month low of $92.94 and a twelve month high of $148.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market capitalization of $520.37 billion, a PE ratio of 39.88, a price-to-earnings-growth ratio of 1.54 and a beta of 0.42. The stock’s 50 day moving average is $127.89 and its 200-day moving average is $131.61.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The company had revenue of $9.82 billion during the quarter, compared to analyst estimates of $9.91 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.01 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a $0.5126 dividend. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 24.66%.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, October 10th. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and an average price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.